Risks

Negative interest coverage and a highly levered capital structure versus peers increase refinancing and dilution risk, limiting flexibility if clinical or commercial milestones slip.

A current ratio near 1.1 versus better-capitalized biotech peers leaves little liquidity cushion, so any trial delay or financing gap could pressure execution and valuation.

Extremely weak cash-conversion metrics versus peers indicate heavy working-capital strain, which can force earlier capital raises and reduce bargaining power with partners.

Absent positive FCF margin versus peers, the company remains dependent on external funding, making it more vulnerable to market access and risk-off biotech sentiment.

Opportunities

If ALLR can advance development without major capital disruption, its negative net debt position versus leveraged peers could preserve optionality and reduce near-term balance-sheet drag.

A modest liquidity buffer relative to distressed micro-cap peers may support short-term operating continuity, improving the odds of reaching value-inflection events.

Should sector financing conditions improve, smaller-cap biotech names like ALLR can re-rate quickly versus larger peers because incremental clinical progress has outsized valuation impact.

Overall Score

ALLR’s forward positioning is constrained by weak liquidity, poor coverage, and heavy funding dependence versus peers, while only limited upside exists from maintaining optionality and reaching clinical milestones.